Aim
Women who developed vestibulodynia (vulvar vestibulitis) while taking combined hormonal contraceptives (CHCs) and a control group of women were tested for polymorphisms of the gene coding for the androgen receptor (AR) that is located on the X chromosome.
Study Design
DNA from 30 women who developed vestibulodynia while taking CHCs and 17 control women were tested for the number of cytosine–adenine–guanine (CAG) trinucleotide repeats in the AR. In addition, serum-free testosterone was tested in both groups.
Results
The mean number of CAG repeats in the study group was significantly greater than the control group (22.05±2.98 vs. 20.61±2.19, respectively; P =0.025). This significant difference persisted when analyzing the CAG repeats from the longer allele from each subject. Among those who were taking drospirenone-containing CHCs, the mean calculated free testosterone was 0.189±0.115ng/dL in the study group and 0.127±0.054ng/dL in the control group, all of whom were taking drospirenone-containing CHCs (P =0.042).
Conclusion
In the study cohort, women who developed vestibulodynia while taking CHCs are more likely to have longer CAG repeats in the AR than women who took the same type of CHC but did not develop vestibulodynia. We speculate that the risk of developing CHC-induced vestibulodynia may be due to lowered free testosterone combined with an inefficient AR that predisposes women to vestibular pain.
Medications in early phase trials show promise for the treatment of FSD. These therapies focus on treating many possible causes of FSD. Concerns over gender bias within the FDA need to be resolved given the need for new treatment options for FSD.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.